
May 31, 2019 | Blog
Parkinson’s Disease Clinical Trials: How Close Are We to Disease-Modifying Therapies?
PART I of CBPartners' CNS series: as the scientific and regulatory barriers in Parkinson’s disease are beginning to be addressed, biotechnology firms are developing innovative therapies based on academic studies showing potential therapeutic targets and pathways, which have been generated with increasing quantity over the past few years using genetic and pre-clinical studies.